GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products worldwide. The company operates in two segments, Pharmaceuticals and Consumer Healthcare. The Pharmaceutical segment offers prescription pharmaceuticals and vaccines. Its primary pharmaceutical products include medicines in nine therapeutic areas, including central nervous system, respiratory, anti-virals, anti-bacterials, vaccines, oncology and emesis, metabolic, cardiovascular, and urogenital. The Consumer Healthcare segment provides various over-the-counter medicines, oral care, and nutritional healthcare products.
One of the top five pharmaceutical firms in the world, GSK’s top sellers include asthma medication Advair. Other bestsellers include anti-depressants Paxil and Wellbutrin, migraine therapy Imitrex, antibiotic Augmentin, and erectile dysfunction drug Lavitra. The company’s consumer products include Tums for sour stomachs and cold sore fighter Abreva. For smokers GSK offers several cessation products like Commit, NicoDerm, and Nicorette.
Glaxosmithkline plc
980 Great West Road
Brentford, TW8 9GS
Phone: 44 20 8047 5000
Fax: 44 20 8047 7807
Allegations that pharmaceutical giant GlaxoSmithKline (GSK) systematically bribed doctors in China are credible, says an investigator hired by the firm.
Peter Humphrey was hired only to investigate who was behind a suspected smear campaign against GSK.
But after he finished his report, he learned the details of further allegations against the firm and told colleagues he believed they were true
Secret emails reveal that the UK’s biggest drug company distorted trial results of an anti-depressant, covering up a link with suicide in teenagers.
Panorama reveals that GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials.
And that GSK-employed ghostwriters influenced ‘independent’ academics
GlaxoSmithKline has agreed to pay out $70m (£36.9m) to settle numerous civil claims of price-fixing in the US.
Several states, health plans and numerous consumers had launched legal action against the group claiming it had inflated the price of some drugs
GlaxoSmithKline (GSK) has agreed to pay $14m (£8m) to settle US claims that it fraudulently tried to delay competitors to anti-depressant drug Paxil.
It agreed the deal with Eliot Spitzer, New York Attorney General, who brought the case on behalf of 49 states.
GSK was accused of using frivolous patent-infringement lawsuits against generic producers of Paxil, keeping the drug’s cost higher than necessary
GlaxoSmithKline shares have fallen almost 2% amid fears a US inquiry into manufacturing quality could be widened and may possibly lead to a big fine.
On 4 March the US Food and Drug Administration (FDA) seized batches of two drugs from the Puerto Rico plant.
Regulators said its diabetes treatment Avandamet and anti-depressant Paxil CR tablets failed to meet safety standards – but did not pose a health risk
A landmark legal complaint against British drug maker GlaxoSmithKline (GSK) over its Aids drug pricing and policies in South Africa will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go forward, according to AidsHealthcare Foundation (AHF).
Instead, GSK simply filed a required legal response to the complaint, AHF said.
The complaint was filed with South Africa’s Competition Tribunal in August by AHF, the US’ largest Aids organisation and several other South African Aids advocates
GlaxoSmithKline (GSK) is facing a US lawsuit alleging that it covered up negative research findings on its anti-depressant drug Paxil.
The lawsuits were filed on behalf of children and teenagers who were prescribed Paxil, known as Seroxat in the UK and Europe.
They claim GSK suppressed data showing that Paxil increased suicidal tendencies in young people
The city of New York has sued drug maker GlaxoSmithKline, claiming that the company engaged in “anticompetitive, fraudulent, and inequitable conduct,” when it acquired patents for its anti-depressant Paxil.
The suit, filed in federal court in Philadelphia, accuses the company of unfairly keeping generic versions of the drug off the market by obtaining more than a dozen “frivolous” patents on Paxil over the past decade.
The complaint accused the company of violating antitrust laws and seeks repayment of the millions of dollars the city has spent purchasing Paxil for New York residents through the Medicaid program
A drug manufacturer being investigated for possible antitrust violations because it cut off shipments to Canadian mail-order pharmacies has to turn its records over to the Minnesota attorney general’s office, a judge has ruled.
Hennepin County District Judge Peter Albrecht also gave a boost to Gov. Tim Pawlenty’s drug-importation Web site, ruling that not all drug importation is illegal
Pennsylvania Attorney General Pappert Recovers $11.1 Million for PA Medicaid Program in Settlements With Bayer and GlaxoSmithKline Over Allegations of Prescription Drug Pricing Fraud
HARRISBURG, Pa., Jan